ArriVent Q1 net loss $43.3M; cash $326.4M; Phase 3 firmonertinib data mid-2026

ArriVent BioPharma, Inc.

2026-Q1 EPS reported -$0.96

Net loss of $43.3M for Q1 2026 versus $64.4M in Q1 2025; R&D expenses $37.6M (down 39% YoY).
Cash and investments $326.4M as of March 31, 2026, expected to fund operations into 4Q 2027.
Topline Phase 3 FURVENT data for firmonertinib in first-line EGFR exon 20 insertion NSCLC expected mid-2026.
FDA IND clearance for ARR-002 (MUC16/NaPi2b dual-target tetravalent ADC) for ovarian/endometrial cancers; first patient dosing in 2H 2026.
ARR-217 (CDH17 ADC) first patient dosed March 2026; dose escalation ongoing for gastrointestinal malignancies.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ArriVent BioPharma, Inc. reported first quarter ended March 31, 2026 results: net income Net loss was $43.3 million and $64.4 million for the three months ended March 31, 2026 and 2025, respectively..

Period: first quarter ended March 31, 2026
Net income: Net loss was $43.3 million and $64.4 million for the three months ended March 31, 2026 and 2025, respectively.
Result: reported results

Exact text from the filing

Net loss was $43.3 million and $64.4 million for the three months ended March 31, 2026 and 2025, respectively.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

ArriVent BioPharma, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-058638

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.